Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | KCNT1 | Q5JUK3 | 2/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19968890 | 0.92 | HMOX1 (0.37) | TP53THRBRBP4MAPTSCN1A | |
| SCHEMBL19968902 | 0.91 | GALR2 (0.38) | TP53RBP4MAPTHTR6SCN9A | |
| SCHEMBL19968894 | 0.91 | GALR2 (0.38) | TP53RBP4MAPTHTR6SCN9A | |
| SCHEMBL19951381 | 0.87 | RBP4 (0.36) | TP53RBP4MAPTHTR6SCN9A | |
| SCHEMBL19968895 | 0.83 | HMOX1 (0.37) | MAPTSCN1ASCN8AKCNT1 | |
| SCHEMBL19927799 | 0.83 | RBP4 (0.36) | TP53RBP4HTR6SCN9ACNR1 | |
| SCHEMBL19951333 | 0.83 | RBP4 (0.36) | TP53RBP4HTR6SCN9ACNR1 | |
| SCHEMBL19925790 | 0.81 | NR3C1 (0.37) | TP53THRBHTR6SCN9ASCN1A | |
| SCHEMBL29464476 | 0.81 | NR3C1 (0.37) | TP53THRBHTR6SCN9ASCN1A | |
| SCHEMBL19968878 | 0.81 | SCN1A (0.38) | TP53THRBMAPTSCN9ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | TP53 3115/4885THRB 2723/4885RBP4 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.